Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has reported a loss for its first fiscal quarter (ending March 31) of $-0.23 versus $1.09 for the same period a year ago — a decline of -121%. This result fell short of the consensus estimate of $4.37 by $-4.60. For the latest four quarters through March 31, E.P.S. were $5.23 compared to $-2.48 a year ago.
Recent Price Action
On 5/1/24, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) stock declined slightly by -0.4%, closing at $110.31. Moreover, above average trading volume at 121% of normal accompanied the decline. The stock has risen 0.6% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
JAZZ’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
Jazz Pharmaceuticals plc has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Jazz Pharmaceuticals plc has a very high Appreciation Score of 85 but a poor Power Rating of 26, triggering the Neutral Value Trend Rating.
Rating Review
In light of this discouraging new earnings information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment